STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures (STEP)
Primary Purpose
Peripheral Arterial Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Arterial closure to ensure hemostasis at femoral artery puncture points
Proglide® (Abbott)
Femoseal® (Terumo)
Arterial closure to ensure hemostasis at femoral artery puncture points
Sponsored by
About this trial
This is an interventional other trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria:
- Age > 18 years,
- Patient with peripheral arterial disease
- Endovascular examination or treatment compatible with a 5F to 7F sheath
- Walking ability
- Patient affiliated with a social security scheme
- Patient's signed informed consent form
Exclusion Criteria:
- Under-age patient
- Patient of age, but under legal guardianship or care
- Contraindication to endovascular treatment
- Use of a 8F or greater sheath
- Morbidity contraindicating same-day walking
- History of ipsilateral open common femoral artery surgery
- Stent at the puncture site
- Radial or brachial puncture
- Antegrade femoral puncture
- Acute ischemia
- Life expectancy of less than one month
- Patient refusal to take part in the study
- Participation in another therapeutic trial
- Pregnant woman
- Allergy to clopidogrel or aspirin
Sites / Locations
- CHU Angers
- CHU Brest
- CH de Cholet
- CHD La Roche-sur-Yon
- CHU de Poitiers
- CHU de Rennes
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Arterial closure device used is Proglide® (Abbott)
Arterial closure device used is Femoseal® (Terumo)
Arm Description
Outcomes
Primary Outcome Measures
Technical success defined as hemostasis at the puncture site without major complications.
Secondary Outcome Measures
Occurrence of major cardio-vascular events
Occurrence of major punctured femoral artery events during the perioperative period
Occurrence of minor punctured femoral artery events during the perioperative period
Walking ability
Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.
Quality of life evaluation (EQ-5D)
Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott)
The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03192033
Brief Title
STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
Acronym
STEP
Official Title
STEP: Proglide® Versus Femoseal®: A Randomized Controlled Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
December 4, 2017 (Actual)
Primary Completion Date
June 25, 2019 (Actual)
Study Completion Date
June 25, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nantes University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Over the past years, arterial closure systems have tended to replace manual compression to ensure hemostasis at femoral artery puncture points. Arterial closure systems reduce hemostasis and patient immobilization times, thus enabling early resumption of walking. These devices have contributed extensively to the development of outpatient stays for cardiology, vascular and neuro-radiology procedures.
However, main arterial closure devices use different technology to close the arterial puncture point. For some, hemostasis is achieved by sealing the arteriotomy between two discs (an inner and an outer). For others, they are designed to close puncture sites delivering a single monofilament polypropylene suture mediated by needles.
The investigators hypothesis is based on a different efficacy between both arterial closure devices for peripheral arterial disease (PAD) patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A duplex scan guided retrograde femoral puncture is performed followed by the use of a closure arterial device to ensure hemostasis. Patients are randomly assigned to be closed by Proglide® (Abbott) versus Femoseal® (Terumo)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
233 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Arterial closure device used is Proglide® (Abbott)
Arm Type
Other
Arm Title
Arterial closure device used is Femoseal® (Terumo)
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
Arterial closure to ensure hemostasis at femoral artery puncture points
Intervention Description
Arterial closure devices used: Proglide® (Abbott)
Intervention Type
Device
Intervention Name(s)
Proglide® (Abbott)
Intervention Description
Arterial closure device used: Proglide® (Abbott)
Intervention Type
Device
Intervention Name(s)
Femoseal® (Terumo)
Intervention Description
Arterial closure device used: Femoseal® (Terumo)
Intervention Type
Other
Intervention Name(s)
Arterial closure to ensure hemostasis at femoral artery puncture points
Intervention Description
Arterial closure device used: Femoseal® (Terumo)
Primary Outcome Measure Information:
Title
Technical success defined as hemostasis at the puncture site without major complications.
Time Frame
Hour 5
Secondary Outcome Measure Information:
Title
Occurrence of major cardio-vascular events
Time Frame
Month 1
Title
Occurrence of major punctured femoral artery events during the perioperative period
Time Frame
Hour 5
Title
Occurrence of minor punctured femoral artery events during the perioperative period
Time Frame
Hour 5
Title
Walking ability
Description
Time before restart of the ambulation measured in minutes from when the sheath of the introducer of the arterial closure system is removed and the moment when the patient is able to walk 100 meters without the recurrence of bleeding.
Time Frame
Hour 5
Title
Quality of life evaluation (EQ-5D)
Time Frame
Month 1
Title
Cost-Outcome Ratio of patient care with FemoSeal® (St Jude) and Proglide® (Abbott)
Description
The measure of effectiveness will be the utility obtained from the EQ-5D quality of life questionnaire
Time Frame
Month 1
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age > 18 years,
Patient with peripheral arterial disease
Endovascular examination or treatment compatible with a 5F to 7F sheath
Walking ability
Patient affiliated with a social security scheme
Patient's signed informed consent form
Exclusion Criteria:
Under-age patient
Patient of age, but under legal guardianship or care
Contraindication to endovascular treatment
Use of a 8F or greater sheath
Morbidity contraindicating same-day walking
History of ipsilateral open common femoral artery surgery
Stent at the puncture site
Radial or brachial puncture
Antegrade femoral puncture
Acute ischemia
Life expectancy of less than one month
Patient refusal to take part in the study
Participation in another therapeutic trial
Pregnant woman
Allergy to clopidogrel or aspirin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Philippe CHAILLOU, Doctor
Organizational Affiliation
Nantes University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
CHU Angers
City
Angers
Country
France
Facility Name
CHU Brest
City
Brest
Country
France
Facility Name
CH de Cholet
City
Cholet
Country
France
Facility Name
CHD La Roche-sur-Yon
City
La Roche-sur-Yon
Country
France
Facility Name
CHU de Poitiers
City
Poitiers
Country
France
Facility Name
CHU de Rennes
City
Rennes
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34386892
Citation
Goueffic Y, Picquet J, Schneider F, Kaladji A, Marret O, Muller L, Guyomarc'h B, Riche VP, Chaillou P, Guillou M, Nasr B. A Randomized Trial Comparing Polymer Versus Suture-Based Vascular Closure Devices for Arterial Closure Following Lower-Limb Arterial Endovascular Revascularization. Cardiovasc Intervent Radiol. 2021 Dec;44(12):1883-1892. doi: 10.1007/s00270-021-02940-z. Epub 2021 Aug 13.
Results Reference
derived
Learn more about this trial
STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures
We'll reach out to this number within 24 hrs